USP22 and cancer: In addition to the heightened oncogenic gene expression caused directly by Wnt pathway overactivation, there are stepwise accumulations of gene mutations, such as TGF‐β, p53and PI3K, which cause cancer progression.47, 48 Targeting the USP22/Wnt/β‐catenin pathway should therefore be considered as one component of a more comprehensive treatment strategy.